Reading view
SortedRL: Accelerating RL Training for LLMs through Online Length-Aware Scheduling
Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer
J Inflamm Res. 2026 Mar 17;19:581764. doi: 10.2147/JIR.S581764. eCollection 2026.
ABSTRACT
Immune checkpoint inhibitors (ICIs) have significantly improved the clinical outcomes for patients with non-small cell lung cancer (NSCLC). However, patient heterogeneity and the limitations of current biomarkers contribute to variations in therapeutic responses. Identifying potential beneficiaries of immunotherapy and predicting efficacy remain critical challenges. In recent years, artificial intelligence (AI) has become increasingly applied in cancer treatment, particularly for modeling clinical data and predicting patient prognosis. By integrating multi-omics data such as radiomics, pathomics, genomics, transcriptomics, proteomics, and microbiomics, AI enables comprehensive biomarker discovery and facilitates prediction of immunotherapy responses and potential toxicities in NSCLC patients. Despite these advancements, challenges such as data standardization, limited interpretability, and technical barriers persist. This review summarizes the application of AI in predicting immunotherapy efficacy for NSCLC patients and discusses the challenges and future directions in the context of precision medicine.
PMID:41867453 | PMC:PMC13005593 | DOI:10.2147/JIR.S581764
Insulin resistance prediction from wearables and routine blood biomarkers
Nature, Published online: 16 March 2026; doi:10.1038/s41586-026-10179-2
A machine-learning model that integrates data from wearable devices (such as smartwatches) with blood biomarkers and demographic data can predict whether someone has insulin resistance, enabling timely lifestyle interventions to prevent progression to type 2 diabetes.